Huahai Pharmaceutical announced that the company's subsidiaries Huaotai and Huabo Biotech have received the “Drug Clinical Trial Approval Notice” for injectable HB0043 approved and issued by the State Drug Administration. Hb0043 is a recombinant humanized IgG1 bispecific antibody targeting human interleukin-17A and human interleukin-36 receptors. It has high binding and blocking activity, and has been developed to treat various autoimmune diseases. At present, the company has invested about 69.09 million yuan in R&D expenses on this project. Pharmaceutical product development cycles are long, there are uncertainties, and the competitive situation will change in the future.

Zhitongcaijing · 07/31/2025 09:17
Huahai Pharmaceutical announced that the company's subsidiaries Huaotai and Huabo Biotech have received the “Drug Clinical Trial Approval Notice” for injectable HB0043 approved and issued by the State Drug Administration. Hb0043 is a recombinant humanized IgG1 bispecific antibody targeting human interleukin-17A and human interleukin-36 receptors. It has high binding and blocking activity, and has been developed to treat various autoimmune diseases. At present, the company has invested about 69.09 million yuan in R&D expenses on this project. Pharmaceutical product development cycles are long, there are uncertainties, and the competitive situation will change in the future.